Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2002, p. 946-952, Vol. 22, No. 3
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.22.3.946-952.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Jason W. Gill,1 Elise S. Randle-Barrett,1 Louise Barnett,2 Frank Koentgen,2,
Gavin W. Lambert,3 Richard P. Harvey,4,5 Richard L. Boyd,1 and Brendan J. Classon1
Department of Pathology and Immunology, Monash Medical School,1 Baker Medical Research Institute, Prahran, Victoria 3181,3 The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050,2 Victor Chang Cardiac Research Institute, St. Vincents Hospital, Darlinghurst, New South Wales 2010,4 Departments of Medicine and Life Sciences, University of New South Wales, Kensington, New South Wales 2052, Australia5
Received 30 August 2001/ Accepted 30 October 2001
|
|
|---|
|
|
|---|
Since TSA-1 is expressed at high levels in the embryonic thymus and adrenal gland and from the very earliest stages of thymopoiesis in the adult, we were interested in studying the consequences of deleting TSA-1 expression in these tissues. We produced a null mutation in the TSA-1 gene in mice by gene targeting in embryonic stem (ES) cells. The resulting, homozygous, TSA-1-deficient (TSA-1-/-) mice exhibit abnormal development and impaired function of the embryonic adrenal gland, although development of the embryonic thymus was apparently normal in these animals. TSA-1-/- embryos die at embryonic day 15.5 (E15.5) of gestation of heart failure associated with severe dilated cardiomyopathy. Using a combination of lymphocyte differentiation assays in vitro and in vivo, we also show that TSA-1 is not an obligate requirement for normal differentiation of T or B cells.
|
|
|---|
![]() View larger version (22K): [in a new window] |
FIG. 1. Disruption of the TSA-1 gene. (A) Exons 2 to 4, encompassing the entire coding region of the TSA-1 protein, were deleted and replaced by the hygromycin phosphotransferase gene cassette (PGK-HYG). WT, wild type. (B) Southern blotting of genomic DNA from primary ES cell clones 216D and 1306B and wild-type W9.5 ES cells. The 3' probe (A) hybridizes to a 7-kb SacI fragment from the wild-type allele and to a 12-kb SacI fragment from the targeted allele.
|
Catecholamine measurements. Catecholamines (adrenaline and noradrenaline) in the adrenal gland and whole body (minus adrenal gland) of E14 embryos were quantified by high-performance liquid chromatography with electrochemical detection, as previously described (13).
Fetal thymic organ culture, lymphoid reconstitution of RAG mice, and flow cytometry analysis.
Thymus glands were removed from E14 embryos and cultured for 7 days as previously described (30). Cell suspensions were made by gently crushing the lobes under a glass coverslip in 100 µl of phosphate-buffered saline (PBS) plus 2% fetal calf serum and 0.02% azide and then immediately adjusting the volume to 1 ml. Fetal livers were dissected from E14 embryos, gently crushed with glass slides in sterile PBS, and washed twice in PBS. Approximately 2 x 106 viable cells were injected intravenously via the tail vein into 10-week-old RAG-1-/- mice which had been gamma irradiated with 300 rads 6 h previously. After 7 weeks, recipient mice were assessed for lymphoid reconstitution by analysis of peripheral blood lymphocytes (PBLs) using fluorescence-activated cell sorter analysis. PBLs were obtained from 200 µl of heparinized treated blood after removal of red cells using lysis buffer (Sigma), followed by two washes in the PBS-fetal calf serum-azide mixture. Approximately 106 PBLs or thymocytes from cultured thymus lobes were incubated for 20 min at 4°C with the appropriately diluted MAbs. After washing, cells were analyzed using a FACScan (Becton Dickinson). Lymphocytes were selected on the basis of forward and side scatter characteristics. Typically, data from 3 x 104 cells were collected for analysis. The MAbs used for marker analysis were GR12 (gift from A. Kosugi), M1/70 (CD11b), CD3
-FITC, CD4-PE, CD8-biotin, B220-PE,
ßTCR-FITC, and
ßTCR-APC. Biotinylated antibodies were detected with streptavidin-Tricolor. All antibodies were from Pharmingen unless otherwise stated.
Analysis of TSA-1 expression in embryonic hearts by RT-PCR. For reverse transcriptase PCR (RT-PCR), RNA was prepared using the acid phenol method and reverse transcription was carried out with H- RT (Promega) and priming with oligo(dT). PCR amplification of first-strand cDNA was performed for 23, 27, 30, and 35 cycles using the following primer pairs: TSA-1 (5'-GCAGAGCCAACAAGCTAAG-3' and 5'-GGCCTCTTCACCCGGAG-3') and ß-actin (5'-ATGGATGACGATATCGCTG-3' and 5'-ATGAGGTAGTCTGTCAGGT-3'). PCR products were resolved on 1.3% agarose gels and visualized by staining with ethidium bromide.
|
|
|---|
Analysis of TSA-1-deficient mice. Heterozygous mice carrying the TSA-1 null allele were mated to produce homozygous TSA-1-/- offspring. However, at 3 weeks of age, no viable TSA-1-/- animals were obtained, as determined by Southern blotting, suggesting that this phenotype is embryonically lethal (Fig. 2A). Genotyping of embryos by Southern blot analysis was therefore undertaken to identify TSA-1-/- animals. At E10.5, viable homozygous embryos were seen (Fig. 2B), and up until stage E14 of embryonic development, normal embryos representative of all three genotypes were identified in the expected Mendelian ratios (Fig. 2A). At E13.5, TSA-1-/- mice were not readily distinguishable from wild-type or heterozygous littermate control animals (Fig. 2C, upper panel). However, at E14.5, many TSA-1-/- embryos were pale and smaller than heterozygous and wild-type littermate control animals (Fig. 2C, lower panel). By E16, all TSA-1-/- embryos were necrotic and undergoing resorption. Similar findings were seen for mice created from the 1306B ES cell line, suggesting that the phenotype was unlikely to have derived from an ES cell mutation arising in vitro (data not shown). Mice derived from the 216D ES clone (with a single integration site for the targeting construct) were used in all subsequent analysis.
![]() View larger version (40K): [in a new window] |
FIG. 2. Homozygous TSA-1-/- mice are embryonically lethal. (A) Phenotypes and genotypes of offspring from TSA-1+/- x TSA-1+/- matings, genotyped by Southern blotting of genomic DNA. N, normal morphology; A, abnormal morphology. No live embryos were detected past E15. (B) Southern blotting of genomic DNA from E10 embryos obtained from TSA-1+/- x TSA-1+/- matings. Detection of restriction fragments corresponding to wild-type and targeted alleles was performed as described for Fig. 1. (C) Phenotype of TSA-1-/- embryos. Embryos were dissected from yolk sacs, and tail biopsies were taken for genotyping.
|
![]() View larger version (64K): [in a new window] |
FIG. 3. Adrenal gland abnormalities in TSA-1-/- mice. A comparison of E14 adrenal gland morphology in wild-type (a) and TSA-1-/- embryos (f). Note the disrupted cellular structure in the TSA-1-/- gland. Analysis of TSA-1 expression by immunostaining (b) and in situ hybridization (c) in E13.5 and E14.5 wild-type embryos, respectively. Immunostaining and in situ analysis reveal the absence of TSA-1 protein and mRNA in TSA-1-/- adrenal glands as expected (g and h, respectively). Medullary chromaffin cells are present in wild-type (d) adrenal glands and TSA-1-/- (i) E14 embryonic adrenal glands, as revealed by immunostaining with an anti-TH antibody. PNMT is present in wild-type (e) but not the TSA-1-/- (j) adrenal gland. Panels k to m show catecholamine analysis of adrenal glands and whole body (minus adrenal gland) from wild-type and TSA-1-/- E13 embryos. Adrenaline is virtually absent (k), and noradrenaline levels are reduced by approximately 50% (l) in the adrenal glands of TSA-1-/- mice. Noradrenaline levels in the whole animal are similar for wild-type and TSA-1-/- mice (m).
|
![]() View larger version (62K): [in a new window] |
FIG. 4. Histological anomalies in the developing hearts of TSA-1-/- mice. A comparison of transverse sections from an E14 wild-type fetus (a) and a TSA-1-/- mutant (b). Ventricle walls and interventricular septa are indicated by arrows. Atria of a wild-type E14 (c) and mutant embryo (d). Expression of TSA-1 by immunohistological staining in the aorta (arrowheads) of wild-type E12 (e) and mutant embryo (f). A comparison of sagittal sections of E13 wild-type (g) and mutant embryo (h) showing normal heart valves (arrowheads) in wild-type and mutant embryos. mRNA analysis of TSA-1 expression by RT-PCR in embryonic E13 and E14 hearts (i). Control samples are thymus (T), an olfactory epithelial cell line (E), and no template DNA (N). The TSA-1 oligonucleotide primer target sequences are separated by a 2,000-bp intron (4) and thus would not be expected to amplify TSA-1 genomic sequences.
|
ßTCR- CD4- CD8- phenotype; therefore, acquisition of these markers can be used to follow the appearance of more mature T-cell subsets which derive from intrathymic precursor cells (23). The data shown in Fig. 5A clearly show the presence of
ßTCR+ cells in both wild-type and TSA-1-/- cultured thymic lobes, and all thymocyte subsets, defined by the CD4 and CD8 markers, were present in both wild-type and TSA-1-/- cultured lobes (Fig. 5A). Specifically, percentages of the major intermediate CD4+ CD8+ population and the more mature CD4- CD8+ and CD4+ CD8- single positive subsets did not differ significantly between wild-type and TSA-1-/- cultured lobes (Fig. 5A). Analysis of the most immature triple-negative CD3- CD4- CD8- thymocyte subsets, using the CD25 and CD44 markers (9), also revealed no significant differences in T-cell phenotype between wild-type and TSA-1-/- cultured lobes (data not shown). Cell yields at the completion of the culture period were 2.6 x 105 and 2.8 x 105 cells 2per lobe for wild-type and TSA-1-/- samples, respectively. These values are within the normal range for this culture system (20) and reveal that no significant differences in the kinetics of in vitro T-cell differentiation arise as a consequence of deleting TSA-1 expression.
![]() View larger version (27K): [in a new window] |
FIG. 5. TSA-1 is not an obligate requirement for T- or B-lymphoid differentiation. (A) Fetal thymic organ culture of E14 thymic lobes from wild-type (TSA-1+/+) and TSA-1-deficient (TSA-1-/-) embryos. Cells were harvested after culturing thymic lobes for 7 days and were analyzed for ßTCR expression (upper panels) and CD4 and CD8 surface marker expression (lower panels) by flow cytometry. (B and C) Lymphoid reconstitution of RAG-1-/- mice with wild-type (TSA-1+/+), heterozygous (TSA-1+/-), and homozygous (TSA-1-/-) hematopoietic precursors from fetal liver. PBLs were harvested from reconstituted animals 7 weeks after engraftment with fetal liver cells. Flow cytometry analysis was carried out using B220 and ßTCR specific MAbs to label B cells and T cells, respectively (B). Numbers shown indicate the percentage of B and T cells present in reconstituted animals. Donor cell TSA-1 genotypes were verified by immunostaining with the TSA-1 specific MAb GR12 (C).
|
|
|
|---|
The gene encoding TSA-1 becomes transcriptionally active midgestation, and, in a previous study, high levels of TSA-1 expression were reported in fetal thymus and hematopoietic precursor cells of the fetal liver (1). We report herein that TSA-1 expression is not restricted to cells of the hematopoietic lineage; TSA-1 is expressed at high levels in the embryonic adrenal gland. We conclude that the abnormal adrenal phenotype of TSA-1-/- mice arises directly as a consequence of extinguishing TSA-1 expression in this organ. The absence of detectable levels of PNMT in TSA-1-/- adrenal glands is consistent with the lack of adrenaline and suggests a primary biosynthetic defect in this tissue. Since PNMT expression is partly dependent on glucocorticoids (17), we are currently investigating whether levels of adrenal glucocorticoids are reduced in TSA-1-/- embryos. It is significant to note that TSA-1 is also expressed at high levels in the human fetal adrenal gland (24).
The cardiac phenotype exhibited by TSA-1-/- mice is less easily reconciled with our expression data. While we were able to detect TSA-1 mRNA in the embryonic mouse heart and others have reported expression of TSA-1 in the human embryonic heart (16), we cannot formally exclude the possibility that the cardiac phenotype of TSA-1-/- mice is secondary in nature. It is unlikely, however, that a catecholamine deficiency adequately explains the cardiac phenotype observed in TSA-1-/- mice. For instance, mice deficient for the glucocorticoid receptor also have a complete lack of adrenaline and reduced levels of noradrenaline (approximately 40% of wild-type levels) in their adrenal glands (5), similar to the adrenal catecholamine data presented herein for TSA-1-/- mice. Glucocorticoid receptor-deficient mice exhibit no obvious cardiac phenotype; rather, they die perinatally as a result of lung abnormalities (5). Mice rendered catecholamine deficient as a result of a targeted mutation in the TH gene are also embryonically lethal at E12 to E14 of gestation (32) and exhibit a cardiac phenotype similar to that of TSA-1-/- mice, in that both types of mice have significantly enlarged atrial chambers and disrupted cellular organization in the ventricular myocardium. However, unlike TSA-1-/- mice, TH-/- mice also show a profound lack of noradrenaline, a major catecholamine of embryogenesis (27). Given that TSA-1-/- adrenal glands express 50% of wild-type noradrenaline levels (Fig. 3l) and that whole-body (minus adrenal gland) noradrenaline levels in TSA-1-/- mice are indistinguishable from those of their wild-type counterparts (Fig. 3m), it is unlikely that reduced catecholamine levels adequately account for the cardiac phenotype in TSA-1-/- mice. To further investigate tissue-specific phenotypes in TSA-1-/- mice, we have recently targeted the TSA-1 locus with loxP sites for temporal and spatial ablation of TSA-1 expression (B. J. Classon and D. J. Zammit, unpublished data).
A surprising finding arising from these studies is the apparently normal progression of both T- and B-lymphoid development in the absence of TSA-1, both in vitro and in vivo. This finding was unusual, given previous reports in which anti-TSA-1 MAbs were shown to profoundly inhibit T-cell development (20), thymocyte apoptosis (19), and IL-2 synthesis by activated T cells (22). This discrepancy raises the possibility that binding the TSA-1 molecule at the cell surface with a MAb constitutes receptor engagement with a multivalent ligand of relatively high affinity, thereby transducing an enhanced, nonphysiological signal to the T cell, rather than inducing a receptor blockade effect. This notion is supported by our most recent work, which shows that monovalent F(ab') fragments of a TSA-1 MAb were unable to block T-cell development in fetal thymic organ culture, whereas F(ab')2 and whole MAb blocked effectively in parallel experiments (21).
TSA-1 is expressed in a number of embryonic and adult tissues, and there is mounting evidence that TSA-1 and other cell membrane Ly-6 superfamily molecules participate in intercellular adhesion and signaling; however, the molecular basis of their function remains obscure. TSA-1 is structurally related to a number of Ly-6 superfamily molecules known to directly bind and regulate the activity of plasma membrane ion channels, including xenoxin-1 (14), calciseptine (7), and caltrin (6). While there is presently no evidence that TSA-1 acts at the level of plasma membrane ion channels, it is significant that MAb blockade of TSA-1 interferes with Ca2+-dependent cellular responses in T cells, such as IL-2 secretion (11, 22). There is previously reported evidence for a cell surface ligand for TSA-1 expressed on thymocytes (3), and further characterization of this structure is expected to clarify the role of TSA-1 in lymphocytes and other tissues.
It will also be of interest to investigate whether TSA-1-/- lymphocytes, which develop apparently normally in vivo, exhibit subtle functional differences compared to their wild-type counterparts, given the reported role for TSA-1 in signal transduction in T cells (12). In this regard, it is significant that, for the only other member of the Ly-6 superfamily for which a gene-deficient mouse has been described, Ly-6A/E, the mutant animals are apparently normal and fertile but exhibit a hyperproliferative T-cell phenotype, the molecular basis of which has not been extensively characterized (26).
In conclusion, the results presented herein demonstrate that TSA-1 is an obligate requirement for normal development and functional compliance of the embryonic adrenal gland, which may have an additional impact on cardiac function in the embryo, and reveal a more generic function for an Ly-6 superfamily molecule in mammalian development.
This work was supported by the National Health and Medical Research Council of Australia.
Present address: Joslin Diabetes Center, Harvard Medical School, Boston, MA 01760. ![]()
Present address: Ozgene, Nedlands Campus, Nedlands, Western Australia 6009, Australia. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»